Pharmesis International Past Earnings Performance
Past criteria checks 0/6
Pharmesis International has been growing earnings at an average annual rate of 29%, while the Pharmaceuticals industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 3.1% per year.
Key information
29.0%
Earnings growth rate
32.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 3.1% |
| Return on equity | -15.5% |
| Net Margin | -17.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pharmesis International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 42 | -7 | 22 | 0 |
| 31 Mar 24 | 44 | -6 | 23 | 0 |
| 31 Dec 23 | 46 | -5 | 24 | 0 |
| 30 Sep 23 | 52 | -3 | 25 | 0 |
| 30 Jun 23 | 59 | -2 | 27 | 0 |
| 31 Mar 23 | 55 | -3 | 27 | 0 |
| 31 Dec 22 | 50 | -4 | 27 | 0 |
| 30 Sep 22 | 48 | -3 | 25 | 0 |
| 30 Jun 22 | 46 | -2 | 24 | 0 |
| 31 Mar 22 | 50 | 0 | 24 | 0 |
| 31 Dec 21 | 53 | 1 | 24 | 0 |
| 30 Sep 21 | 53 | -1 | 26 | 0 |
| 30 Jun 21 | 53 | -2 | 27 | 0 |
| 31 Mar 21 | 50 | -4 | 28 | 0 |
| 31 Dec 20 | 47 | -6 | 28 | 0 |
| 30 Sep 20 | 45 | -13 | 28 | 0 |
| 30 Jun 20 | 38 | -16 | 27 | 0 |
| 31 Mar 20 | 39 | -17 | 28 | 0 |
| 31 Dec 19 | 37 | -18 | 29 | 0 |
| 30 Sep 19 | 42 | -7 | 29 | 0 |
| 30 Jun 19 | 48 | -4 | 29 | 0 |
| 31 Mar 19 | 57 | -2 | 30 | 0 |
| 31 Dec 18 | 64 | 1 | 29 | 0 |
| 30 Sep 18 | 67 | -2 | 31 | 0 |
| 30 Jun 18 | 71 | -1 | 32 | 0 |
| 31 Mar 18 | 70 | -2 | 32 | 0 |
| 31 Dec 17 | 70 | -2 | 32 | 0 |
| 30 Sep 17 | 72 | -4 | 35 | 0 |
| 30 Jun 17 | 71 | -4 | 34 | 0 |
| 31 Mar 17 | 70 | -4 | 34 | 0 |
| 31 Dec 16 | 69 | -5 | 34 | 0 |
| 30 Sep 16 | 65 | 0 | 31 | 0 |
| 30 Jun 16 | 64 | 0 | 31 | 0 |
| 31 Mar 16 | 63 | 1 | 31 | 0 |
| 31 Dec 15 | 62 | 2 | 33 | 0 |
| 30 Sep 15 | 61 | -2 | 34 | 0 |
| 30 Jun 15 | 63 | -3 | 36 | 0 |
| 31 Mar 15 | 61 | -3 | 38 | 0 |
| 31 Dec 14 | 61 | -4 | 37 | 0 |
| 30 Sep 14 | 63 | 1 | 38 | 0 |
| 30 Jun 14 | 62 | 2 | 36 | 0 |
| 31 Mar 14 | 63 | 1 | 37 | 0 |
| 31 Dec 13 | 65 | 0 | 38 | 0 |
Quality Earnings: BFK is currently unprofitable.
Growing Profit Margin: BFK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BFK is unprofitable, but has reduced losses over the past 5 years at a rate of 29% per year.
Accelerating Growth: Unable to compare BFK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BFK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6%).
Return on Equity
High ROE: BFK has a negative Return on Equity (-15.52%), as it is currently unprofitable.